Sonoma Pharmaceuticals Ownership
| SNOA Stock | USD 3.48 0.14 3.87% |
Sonoma |
Sonoma Stock Ownership Analysis
The company has price-to-book ratio of 1.14. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Sonoma Pharmaceuticals recorded a loss per share of 2.26. The entity last dividend was issued on the 20th of June 2019. The firm had 1:20 split on the 30th of August 2024. Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia. Sonoma Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 12 people. To find out more about Sonoma Pharmaceuticals contact Amy Trombly at 800 759 9305 or learn more at https://sonomapharma.com.Besides selling stocks to institutional investors, Sonoma Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Sonoma Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Sonoma Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Sonoma Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Sonoma Pharmaceuticals Insider Trades History
Only 1.25% of Sonoma Pharmaceuticals are currently held by insiders. Unlike Sonoma Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Sonoma Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Sonoma Pharmaceuticals' insider trades
Sonoma Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sonoma Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sonoma Pharmaceuticals backward and forwards among themselves. Sonoma Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Sonoma Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ground Swell Capital, Llc | 2024-12-31 | 0.0 | Jane Street Group Llc | 2024-09-30 | 0.0 | Wells Fargo & Co | 2024-12-31 | 0.0 | Citigroup Inc | 2024-12-31 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 | Qube Research & Technologies | 2024-09-30 | 0.0 | Geode Capital Management, Llc | 2024-09-30 | 0.0 | Xtx Topco Ltd | 2024-09-30 | 0.0 | Two Sigma Securities, Llc | 2024-09-30 | 0.0 | Ubs Group Ag | 2024-12-31 | 17.4 K | Tower Research Capital Llc | 2024-12-31 | 2.4 K |
Sonoma Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sonoma Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sonoma Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sonoma Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mclaughlin John over six months ago Acquisition by Mclaughlin John of 20000 shares of Sonoma Pharmaceuticals at 1.08 subject to Rule 16b-3 | ||
Schutz James J over six months ago Disposition of 28 shares by Schutz James J of Sonoma Pharmaceuticals at 70.35 subject to Rule 16b-3 | ||
Dal Poggetto John over six months ago Acquisition by Dal Poggetto John of 15000 shares of Sonoma Pharmaceuticals subject to Rule 16b-3 | ||
Dal Poggetto John over six months ago Disposition of 1648 shares by Dal Poggetto John of Sonoma Pharmaceuticals at 175.5 subject to Rule 16b-3 | ||
Frederick Sandford over six months ago Acquisition by Frederick Sandford of 400000 shares of Sonoma Pharmaceuticals at 0.717 subject to Rule 16b-3 | ||
Bruce Thornton over a year ago Acquisition by Bruce Thornton of 60000 shares of Sonoma Pharmaceuticals subject to Rule 16b-3 | ||
Bruce Thornton over a year ago Acquisition by Bruce Thornton of 100000 shares of Sonoma Pharmaceuticals subject to Rule 16b-3 |
Sonoma Pharmaceuticals Outstanding Bonds
Sonoma Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Sonoma Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Sonoma bonds can be classified according to their maturity, which is the date when Sonoma Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Sonoma Pharmaceuticals Corporate Filings
10Q | 5th of February 2025 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 30th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 20th of December 2024 Other Reports | ViewVerify | |
| 20th of September 2024 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonoma Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonoma Pharmaceuticals. If investors know Sonoma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonoma Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.26) | Revenue Per Share | Quarterly Revenue Growth 0.136 | Return On Assets | Return On Equity |
The market value of Sonoma Pharmaceuticals is measured differently than its book value, which is the value of Sonoma that is recorded on the company's balance sheet. Investors also form their own opinion of Sonoma Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Sonoma Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonoma Pharmaceuticals' market value can be influenced by many factors that don't directly affect Sonoma Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonoma Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonoma Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonoma Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.